Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3251-3258

  Ujiie, Hideki ^a,b   Tomida, Mikio ^a   Akiyama, Hirohiko ^a   Nakajima, Yuki ^a   Okada, Daisuke ^a   Yoshino, Naoyuki ^a   Takiguchi, Yuichi ^b   Tanzawa, Hideki ^b  

^a SAITAMA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

c Met; EGFR; Epidermal growth factor receptor; Hepatocyte growth factor; Hepatocyte growth factor receptor; HGF; IL 6; Interleukin 6; Non small cell lung cancer; NSCLC; Prognostic markers

Indexed keywords

INTERLEUKIN 6; NICOTINAMIDE METHYLTRANSFERASE; SCATTER FACTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865676436     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Tomida M, Mikami I, Takeuchi S, Nishimura H and Akiyama H: Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol 135: 1223-1229, 2009.
2. Tomida M, Ohtake H, Yokota T, Kobayashi Y and Kurosumi M: STAT3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells. J Cancer Res Clin Oncol 134: 551-559, 2008.
3. Brundage MD, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057, 2002.
4. Nakamura T, Nawa K and Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122: 1450-1459, 1984.
5. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K and Shimizu S: Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
6. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A and Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641, 1992.
7. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK and Comoglio PM: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6: 501-504, 1991.
8. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 53: 35-69, 2005.
9. Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289-300, 2002.
10. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H and Tominaga T: Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 4: 659-664, 1998.
11. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T and Shin S: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54: 1630-1633, 1994.
12. Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A and Toi M: Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 75: 673-677, 1977.
13. Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y and Nakajima M: Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol 18: 2963-2971, 2000.
14. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K and Kusunoki M: Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer 125: 1657-1662, 2009.
15. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT and Salgia R: Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24: 1031-1038, 2004.
16. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A and Waage A: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myelomas. Blood 91: 806-812, 1998.
17. Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, Nielsen JL, Odén A, Seidel C, Waage A, Westin J and Wislöff F: Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 106: 1005-1012, 1999.
18. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y and Tsuneyoshi M: Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 31: 185-192, 2000.
19. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR and Landreneau RJ: Association of immunoreactive hepatocyte growth factor with poor survival in resectable nonsmall cell lung cancer. Cancer Res 57: 433-439, 1997.
20. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT and Landreneau RJ: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66: 1915-1918, 1998.
21. Takanami I, Tanana F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S: Hepatocyte growth factor and c-MET/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 53: 392-397, 1996.
22. Han JY, Kim JY, Lee SH, Yoo NJ and Choi BG: Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer 74: 293-299, 2011.
23. Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N and Nishio K: Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 16: 4616-4624, 2010.
24. Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, Ueno M and Yokomise H: The tumour-stromal interaction between intratumoral c-MET and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small cell lung cancer patients. Br J Cancer 90: 1555-1562, 2004.
25. Tomida M and Saito T: The human hepatocyte growth factor (HGF) gene is transcriptionally activated by leukemia inhibitory factor through the Stat binding element. Oncogene 23: 679-686, 2004.
26. Akira S and Kishimoto T: The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin Cancer Biol 3: 17-26, 1992.
27. Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663, 2007.
28. Li Y, Du H, Qin Y, Roberts J, Cummings OW and Yan C: Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 67: 8494-8503, 2007.
29. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg JF: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007.
30. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ and Harris CC: Serum concentrations of cytokines and lung cancer survival in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 18: 215-222, 2009.
31. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M and Steffen J: Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology 70: 115-125, 2006.
32. TNM Classification of Malignant Tumours SEVENTH EDITION 2009.
33. Kaplan EL and Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
34. Cox DR: Regression models and life tables. J Roy Stat Soc 34: 187-220, 1972.
35. Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito NJ and Oramas J: Cytokine levels (IL-6 and INF-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11: 80-86, 1999.
36. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A and Catalano G: Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5: 649-652, 1998.
37. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Janne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
38. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara M, Mitsudomi T, Yatabe Y, Nakamura T and Sone S: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-9487, 2008.
39. Kutikov A, Makhov P, Golovine K, Canter DJ, Sirohi M, Street R, Simhan J, Uzzo RG and Kolenko VM: Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 78: 968.e7-e11, 2011.
40. Kunioku H, Inoue K, Tomida M: Interleukin-6 protects rat PC12 cells from serum deprivation or chemotherapeutic agents through the phosphatidylinositol 3-kinase and STAT3 pathways. Neurosci Lett 309: 13-16, 2001.
41. Meng Q, Mason JM, Porti D, Goldberg ID, Rosen EM and Fan S: Hepatocyte growth factor decreases sensitivity to chemotherapeutic agents and stimulates cell adhesion, invasion, and migration. Biochem Biophys Res Commun 274: 772-779, 2000.
42. Bayliss TJ, Smith JT, Schuster M, Dragnev KH and Rigas JR: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11: 1663-8, 2011.
43. Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Janne PA and Nakagawa K: TAK- 701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 9: 2785-2792, 2010.
44. Saito T and Tomida M: Generation of inhibitory DNA aptamers against human hepatocyte growth factor. DNA Cell Biol 24: 624-633, 2005.